Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability) (Stock Code: 286)

## **APPOINTMENT OF VICE PRESIDENT OF THE GROUP**

This announcement is voluntary made by Common Splendor International Health Industry Group Limited ("**Company**").

The board of directors ("**Board**") of the Company is pleased to announce that Mr. Wu Luosheng ("**Mr. Wu**") has been appointed as a Vice President of the Company and its subsidiaries (together the "**Group**") with effect from 18 May 2017.

The biographical details of Mr. Wu are set out below:

Mr. Wu Luosheng is an experienced personnel in biological medicine production. Mr. Wu studied in low temperature blood preparation technology in the Ministry of Health Shanghai Biological Products Research Institute\* (衛生部上海生物研究所) from November 1987 to December 2009 for 22 years. Mr. Wu worked in the blood preparation industry from frontline production to senior management posts. After that, Mr. Wu worked in a pharmaceutical factory as general manager responsible for its overall operation.

Throughout the years, Mr. Wu accumulated extensive biological medicine production and management experience. Mr. Wu's high efficiency and practical enterprise management experience is well recognized among the industry. Mr. Wu graduated from Henan University of Technology and obtained a Bachelor degree in Business Administration. He also obtained Pharmacist and Pharmaceutical Engineer job titles.

The Board would like to extend its welcome to Mr. Wu for joining the Group particularly for the appointment of Mr. Wu to lead our Group's business development in the area of biological medicine production.

By order of the Board Common Splendor International Health Industry Group Limited Cheung Wai Kuen Chairman

Hong Kong, 18 May 2017

As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors and Mr. Lin Jiang and Mr. Bai Yinghai as non-executive Directors and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Lam Chi Wing as independent non-executive Directors.

\* For identification purposes only